

<b>Product Name</b>	: DMH-25
<b>Synonyms</b>	: —
<b>Cat No.</b>	: M22216
<b>CAS Number</b>	: 1685280-21-0
<b>Molecular Formula</b>	: C <sub>15</sub> H <sub>8</sub> Br <sub>3</sub> NO <sub>3</sub>
<b>Formula Weight</b>	: 489.94
<b>Chemical Name</b>	: —
<b>Description</b>	DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells. In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology. Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers.
<b>Pathway</b>	: PI3K/Akt/mTOR signaling
<b>Target</b>	: mTOR
<b>Receptor</b>	: mTOR
<b>Solubility</b>	: —
<b>SMILES</b>	: O=[N+](C(C(C1=CC=C(Br)C=C1)O2)=CC3=C2C(Br)=CC(Br)=C3)[O-]
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:

Lamélie, fouqué, Delalande O, Jean M, et al. A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells[J]. Journal of Medicinal Chemistry, 2015:6559-73.